Global Small Cell Lung Cancer Sclc Therapeutics Market
Market Size in USD Billion
CAGR :
% 
USD
10.00 Billion
USD
21.44 Billion
2021
2029
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 10.00 Billion |
 Market Size (Forecast Year) |
USD 21.44 Billion |
 CAGR |
% |
| Major Markets Players |
|
Global Small Cell Lung Cancer (SCLC) Therapeutics Market, By Treatment Type (Chemotherapy, Targeted Therapy, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Size
The global small cell lung cancer (SCLC) therapeutics market is expected to witness significant growth during the forecast period. The factors propelled the growth of Small Cell Lung Cancer (SCLC) therapeutics market are rise in cases of small cell lung cancer (SCLC) across the world and promising pipeline drugs. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global small cell lung cancer (SCLC) therapeutics market in the forecast period 2022-2029. The expected CAGR of global small cell lung cancer (SCLC) therapeutics market is tend to be around 10.0% in the mentioned forecast period. The market was valued at USD 10 billion in 2021, and it would grow upto USD 21.44 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Small cell lung cancer (SCLC) is termed as oat cell carcinoma is a most aggressive type of lung cancers which accounted around 10% to 15% of all lung cancers. In small cell lung cancer (SCLC) abnormal growth of cells originates from the tissues of the in the breathing tubes where it grows very rapidly and form large tumors. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Small Cell Lung Cancer (SCLC) Therapeutics Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Treatment Type (Chemotherapy, Targeted Therapy, Others), Route of Administration (Intravenous, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), CLOVIS ONCOLOGY (U.S.), Johnson & Johnson Private Limited (U.S.) |
|
Market Opportunities |
|
Global Small Cell Lung Cancer (SCLC) Therapeutics Market Dynamics
Drivers
- Increase in Cancer Cases
The rise in cancer cases globally boosts the global small cell lung cancer (SCLC) therapeutics market in the forecast period As per the reports of the American Cancer Society Statistics in 2016, majority of cases of SCLC mostly occur in individuals between the age group of 60-80 years with an estimated global death rate being 30,000 per year. In addition to this, as per the reports of WHO, lung cancer is the second most dominant cancer in men and women causing 1.59 million deaths in 2012. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to increase the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Patent Expiration Encourages New Launches
Patent expiration of old companies can make better opportunities for the new market players. The adoption of combination therapies is a significant factor that contributes to the growth of the small cell lung cancer (SCLC) therapeutics market. Further, R&D fundings are an add-on to the market.
- Development of Diversified Treatments
Treatments such as chemotherapy and radiation therapy are given to the patient to treat early stage of small cell lung cancer. These offer great benefits to the patients. For instance, radiation therapy is given to patients to shrink tumor cells as well as to relieve symptoms such as cough, trouble swallowing, bleeding, and shortness of breath. Techniques such as three-dimensional conformal radiation therapy (3D-CRT) and intensity modulated radiation therapy (IMRT) are the two types of radiation methods that are widely used in the treatment.
- Rising Healthcare Awareness
Awareness among patients as well as healthcare providers about the incidence of small cell lung cancer (SCLC) is on the rise. Patients and doctors are now more actively participating in learning about the therapies that are available for the treatment of these severe diseases. This is one of the most important drivers in the market. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global small cell lung cancer (SCLC) therapeutics market over a forecast period.
- Increasing Cost Of Treatments
The huge expenditure required for the treatment methods surely hamper the market growth. Many of the treatments involved in this disease require high cost and thus at times gets difficult for many people, especially the ones in the rural areas. Thus, this can act as a major hindrance factor for the market.
This global small cell lung cancer (SCLC) therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global small cell lung cancer (SCLC) therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Small Cell Lung Cancer (SCLC) Therapeutics Market Scope
The global small cell lung cancer (SCLC) therapeutics market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Chemotherapy
- Targeted Therapy
- Others
Route of Administration
- Intravenous
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Small Cell Lung Cancer (SCLC) Therapeutics Market Regional Analysis/Insights
The global small cell lung cancer (SCLC) therapeutics market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global small cell lung cancer (SCLC) therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to the presence of key generic pharmaceuticals companies in this region and rise in government initiatives and awareness.
North America dominates the market due to the increase prevalence of small cell lung cancer (SCLC) and large availability of treatment options.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Small Cell Lung Cancer (SCLC) Therapeutics Market Share Analysis
The global small cell lung cancer (SCLC) therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global small cell lung cancer (SCLC) therapeutics market.
Key players operating in the global small cell lung cancer (SCLC) therapeutics market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- CLOVIS ONCOLOGY (U.S.)
- Johnson & Johnson Private Limited (U.S.)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
4.3 SYMPTOMS TYPE
4.3.1 YELLOWING OF THE SKIN
4.3.2 FATIGUE
4.3.3 WEAKNESS
4.3.4 LOSS OF APPETITE
4.3.5 ITCHING
4.3.6 EASY BRUISING
4.3.7 OTHERS
4.4 COMPLICATIONS INSIGHTS
4.4.1 EDEMA AND ASCITES
4.4.2 SPONTANEOUS BACTERIAL PERITONITIS (SBP)
4.4.3 BLEEDING FROM ESOPHAGEAL VARICES
4.4.4 HYPERSPLENISM
4.4.5 LIVER CANCER (HEPATOCELLULAR CARCINOMA)
4.4.6 HEPATIC ENCEPHALOPATHY
4.4.7 HEPATORENAL SYNDROME
4.4.8 HEPATOPULMONARY SYNDROME
5 INDUSTRY INSIGHTS
5.1 MICRO AND MACRO ECONOMIC FACTORS
5.2 PENETRATION AND GROWTH PROSPECT MAPPING
5.3 KEY PRICING STRATEGIES
5.4 INTERVIEWS WITH SPECIALIST
5.5 ANALYIS AND RECOMMENDATION
6 INTELLECTUAL PROPERTY (IP) PORTFOLIO
6.1 PATENT QUALITY AND STRENGTH
6.2 PATENT FAMILIES
6.3 LICENSING AND COLLABORATIONS
6.4 COMPETITIVE LANDSCAPE
6.5 IP STRATEGY AND MANAGEMENT
6.6 OTHER
7 COST ANALYSIS BREAKDOWN
8 TECHNONLOGY ROADMAP
9 INNOVATION TRACKER AND STRATEGIC ANALYSIS
9.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
9.1.1 JOINT VENTURES
9.1.2 MERGERS AND ACQUISITIONS
9.1.3 LICENSING AND PARTNERSHIP
9.1.4 TECHNOLOGY COLLABORATIONS
9.1.5 STRATEGIC DIVESTMENTS
9.2 NUMBER OF PRODUCTS IN DEVELOPMENT
9.3 STAGE OF DEVELOPMENT
9.4 TIMELINES AND MILESTONES
9.5 INNOVATION STRATEGIES AND METHODOLOGIES
9.6 RISK ASSESSMENT AND MITIGATION
9.7 MERGERS AND ACQUISITIONS
9.8 FUTURE OUTLOOK
10 EPIDEMIOLOGY
10.1 INCIDENCE OF ALL BY GENDER
10.2 TREATMENT RATE
10.3 MORTALITY RATE
10.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
10.5 PATIENT TREATMENT SUCCESS RATES
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 PIPELINE ANALYSIS
12.1 CLINICAL TRIALS AND PHASE ANALYSIS
12.2 DRUG THERAPY PIPELINE
12.3 PHASE III CANDIDATES
12.4 PHASE II CANDIDATES
12.5 PHASE I CANDIDATES
12.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR LIVER CIRRHOSIS DRUGS MARKET
Company Name Product Name
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR LIVER CIRRHOSIS DRUGS MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved but Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR LIVER CIRRHOSIS DRUGS MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR LIVER CIRRHOSIS DRUGS MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR LIVER CIRRHOSIS DRUGS MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
13 REIMBURSEMENT FRAMEWORK
14 OPPUTUNITY MAP ANALYSIS
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.1 ECONOMIC DEVELOPMENT
17 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, BY THERAPEUTIC DRUGS
17.1 OVERVIEW
17.2 CHEMOTHERAPY
17.2.1 BY DRUGS
17.2.1.1. CARBOPLATIN
17.2.1.1.1. MARKET VALUE (USD MN)
17.2.1.1.2. MARKET VOLUME (IU)
17.2.1.1.3. AVERAGE SELLING PRICE (USD)
17.2.1.2. CISPLATIN
17.2.1.2.1. MARKET VALUE (USD MN)
17.2.1.2.2. MARKET VOLUME (IU)
17.2.1.2.3. AVERAGE SELLING PRICE (USD)
17.2.1.3. IRINOTECAN
17.2.1.3.1. MARKET VALUE (USD MN)
17.2.1.3.2. MARKET VOLUME (IU)
17.2.1.3.3. AVERAGE SELLING PRICE (USD)
17.2.1.4. ETOPOSIDE
17.2.1.4.1. MARKET VALUE (USD MN)
17.2.1.4.2. MARKET VOLUME (IU)
17.2.1.4.3. AVERAGE SELLING PRICE (USD)
17.2.1.5. LUBRINECTEDIN
17.2.1.5.1. MARKET VALUE (USD MN)
17.2.1.5.2. MARKET VOLUME (IU)
17.2.1.5.3. AVERAGE SELLING PRICE (USD)
17.2.1.6. TOPOTECAN
17.2.1.6.1. MARKET VALUE (USD MN)
17.2.1.6.2. MARKET VOLUME (IU)
17.2.1.6.3. AVERAGE SELLING PRICE (USD)
17.2.1.7. OTHERS
17.3 IMMNUNOTHERAY
17.3.1 ATEZOLIZUMAB (TECENTRIQ)
17.3.1.1. MARKET VALUE (USD MN)
17.3.1.2. MARKET VOLUME (IU)
17.3.1.3. AVERAGE SELLING PRICE (USD)
17.3.2 DURVALUMAB (IMFINZI)
17.3.2.1. MARKET VALUE (USD MN)
17.3.2.2. MARKET VOLUME (IU)
17.3.2.3. AVERAGE SELLING PRICE (USD)
17.3.3 OTHERS
17.4 RADIATION THERAPY
17.4.1 THREE DIMENTIONAL CONFORMAL RADITAION THERAPY (3D-CRT)
17.4.2 INTENSITY MODULATED RADIATION THERAPY (IMRT)
17.4.3 STEREOTACTIVE ABLATIVE THERAPY (SABR)
17.4.4 STEREOTACTIVE RADIOSURGERY (SRS)
17.4.5 OTHERS
17.5 PALLIATIVE PROCEDURES
17.5.1 PHOTODYNAMIC THERAPY
17.5.2 LASER THERAPY
17.5.3 STENT PLACEMENT
17.5.4 THORACENTESIS
17.5.5 PLEURODESIS
17.5.6 PERICARDIOCENTESIS
17.5.7 OTHERS
18 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, BY DRUG TYPE
18.1 OVERVIEW
18.2 GENERICS
18.3 BRANDED
18.3.1 PARAPLATIN
18.3.1.1. MARKET VALUE (USD MN)
18.3.1.2. MARKET VOLUME (IU)
18.3.1.3. AVERAGE SELLING PRICE (USD)
18.3.2 PLATINOL
18.3.2.1. MARKET VALUE (USD MN)
18.3.2.2. MARKET VOLUME (IU)
18.3.2.3. AVERAGE SELLING PRICE (USD)
18.3.3 PLATINO-AQ
18.3.3.1. MARKET VALUE (USD MN)
18.3.3.2. MARKET VOLUME (IU)
18.3.3.3. AVERAGE SELLING PRICE (USD)
18.3.4 ZEPZELCA
18.3.4.1. MARKET VALUE (USD MN)
18.3.4.2. MARKET VOLUME (IU)
18.3.4.3. AVERAGE SELLING PRICE (USD)
18.3.5 TOPOTECAN PHOSPHATE
18.3.5.1. MARKET VALUE (USD MN)
18.3.5.2. MARKET VOLUME (IU)
18.3.5.3. AVERAGE SELLING PRICE (USD)
18.3.6 OTHERS
19 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
19.1 OVERVIEW
19.2 ORAL
19.2.1 TABLETS
19.2.2 CAPSULES
19.2.3 OTHERS
19.3 INJECTABLES
19.3.1 INTRAVENOUS (IV)
19.3.2 SUBCUTANEOUS
19.3.3 INTRAMUSCULAR
19.4 OTHERS
20 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, BY STAGE
20.1 OVERVIEW
20.2 STAGE 0
20.3 STAGE 1
20.4 STAGE 2
20.5 STAGE 3
20.6 STAGE 4
21 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, BY PRODUCT TYPE
21.1 OVERVIEW
21.2 MARKETED DRUG
21.3 PIPELINE DRUG
21.3.1 PHASE III CANDIDATES
21.3.2 PHASE II CANDIDATES
21.3.2.1. ROVALPITUZUMAB
21.3.2.2. OLAPARIB
21.3.2.3. CEDIRANIB
21.3.3 PHASE I/II CANDIDATES
21.3.3.1. APG-1252
21.3.3.2. HPN328
21.3.3.3. OTHERS
21.3.4 PHASE I CANDIDATE
21.3.4.1. BAY 1895344
21.3.4.2. AMG 757
21.3.4.3. OTHERS
21.3.5 OTHERS (PRE-CLINICAL AND RESEARCH)
22 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, BY GENDER
22.1 OVERVIEW
22.2 MALE
22.3 FEMALE
23 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, BY AGE GROUP
23.1 OVERVIEW
23.2 CHILDREN
23.3 ADULT
23.4 GERIATIC
24 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, BY END USER
24.1 OVERVIEW
24.2 HOSPITALS
24.2.1 BY TYPE
24.2.1.1. PUBLIC
24.2.1.2. PRIVATE
24.2.2 BY LEVEL
24.2.2.1. TIER 1
24.2.2.2. TIER 2
24.2.2.3. TIER 3
24.3 SPECIALTY CLINICS
24.4 KIDNEY CARE CENTERS
24.5 AMBULATORY SURGICAL CENTERS
24.6 ACADEMIC & RESEARCH INSTITUTES
24.7 OTHERS
25 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
25.1 OVERVIEW
25.2 DIRECT TENDER
25.3 RETAIL SALES
25.3.1 HOSPITAL PHARMACY
25.3.2 ONLINE PHARMACY
25.3.3 OFFLINE PHARMACY
25.4 OTHERS
26 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, BY GEOGRAPHY
GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
26.1 NORTH AMERICA
26.1.1 U.S.
26.1.2 CANADA
26.1.3 MEXICO
26.2 EUROPE
26.2.1 GERMANY
26.2.2 FRANCE
26.2.3 U.K.
26.2.4 HUNGARY
26.2.5 AUSTRIA
26.2.6 NORWAY
26.2.7 POLAND
26.2.8 ITALY
26.2.9 SPAIN
26.2.10 RUSSIA
26.2.11 TURKEY
26.2.12 BELGIUM
26.2.13 NETHERLANDS
26.2.14 SWITZERLAND
26.2.15 REST OF EUROPE
26.3 ASIA-PACIFIC
26.3.1 JAPAN
26.3.2 TAIWAN
26.3.3 CHINA
26.3.4 SOUTH KOREA
26.3.5 INDIA
26.3.6 AUSTRALIA
26.3.7 SINGAPORE
26.3.8 THAILAND
26.3.9 MALAYSIA
26.3.10 INDONESIA
26.3.11 PHILIPPINES
26.3.12 VIETNAM
26.3.13 REST OF ASIA-PACIFIC
26.4 SOUTH AMERICA
26.4.1 BRAZIL
26.4.2 ARGENTINA
26.4.3 REST OF SOUTH AMERICA
26.5 MIDDLE EAST AND AFRICA
26.5.1 SOUTH AFRICA
26.5.2 SAUDI ARABIA
26.5.3 UAE
26.5.4 EGYPT
26.5.5 KUWAIT
26.5.6 ISRAEL
26.5.7 REST OF MIDDLE EAST AND AFRICA
26.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
27 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, SWOT AND DBMR ANALYSIS
28 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, COMPANY LANDSCAPE
28.1 COMPANY SHARE ANALYSIS: GLOBAL
28.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
28.3 COMPANY SHARE ANALYSIS: EUROPE
28.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
28.5 MERGERS & ACQUISITIONS
28.6 NEW PRODUCT DEVELOPMENT & APPROVALS
28.7 EXPANSIONS
28.8 REGULATORY CHANGES
28.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
29 GLOBAL SMALL LUNG CANCER (SCLC) THERAPEUTICS MARKET, COMPANY PROFILE
29.1 SANOFI
29.1.1 COMPANY OVERVIEW
29.1.2 REVENUE ANALYSIS
29.1.3 GEOGRAPHIC PRESENCE
29.1.4 PRODUCT PORTFOLIO
29.1.5 RECENT DEVELOPMENTS
29.2 BRISTOL MEYERS SQUIBB
29.2.1 COMPANY OVERVIEW
29.2.2 REVENUE ANALYSIS
29.2.3 GEOGRAPHIC PRESENCE
29.2.4 PRODUCT PORTFOLIO
29.2.5 RECENT DEVELOPMENTS
29.3 CADILA PHARMACEUTICALS
29.3.1 COMPANY OVERVIEW
29.3.2 REVENUE ANALYSIS
29.3.3 GEOGRAPHIC PRESENCE
29.3.4 PRODUCT PORTFOLIO
29.3.5 RECENT DEVELOPMENTS
29.4 BOEHRINGER INGELHEIM
29.4.1 COMPANY OVERVIEW
29.4.2 REVENUE ANALYSIS
29.4.3 GEOGRAPHIC PRESENCE
29.4.4 PRODUCT PORTFOLIO
29.4.5 RECENT DEVELOPMENTS
29.5 PFIZER
29.5.1 COMPANY OVERVIEW
29.5.2 REVENUE ANALYSIS
29.5.3 GEOGRAPHIC PRESENCE
29.5.4 PRODUCT PORTFOLIO
29.5.5 RECENT DEVELOPMENTS
29.6 ASTRAZENECA
29.6.1 COMPANY OVERVIEW
29.6.2 REVENUE ANALYSIS
29.6.3 GEOGRAPHIC PRESENCE
29.6.4 PRODUCT PORTFOLIO
29.6.5 RECENT DEVELOPMENTS
29.7 F-HOFFMANN LA ROCHE
29.7.1 COMPANY OVERVIEW
29.7.2 REVENUE ANALYSIS
29.7.3 GEOGRAPHIC PRESENCE
29.7.4 PRODUCT PORTFOLIO
29.7.5 RECENT DEVELOPMENTS
29.8 REGENERON
29.8.1 COMPANY OVERVIEW
29.8.2 REVENUE ANALYSIS
29.8.3 GEOGRAPHIC PRESENCE
29.8.4 PRODUCT PORTFOLIO
29.8.5 RECENT DEVELOPMENTS
29.9 MERCK & CO., INC
29.9.1 COMPANY OVERVIEW
29.9.2 REVENUE ANALYSIS
29.9.3 GEOGRAPHIC PRESENCE
29.9.4 PRODUCT PORTFOLIO
29.9.5 RECENT DEVELOPMENTS
29.1 AMGEN
29.10.1 COMPANY OVERVIEW
29.10.2 REVENUE ANALYSIS
29.10.3 GEOGRAPHIC PRESENCE
29.10.4 PRODUCT PORTFOLIO
29.10.5 RECENT DEVELOPMENTS
29.11 NOVARTIS AG
29.11.1 COMPANY OVERVIEW
29.11.2 REVENUE ANALYSIS
29.11.3 GEOGRAPHIC PRESENCE
29.11.4 PRODUCT PORTFOLIO
29.11.5 RECENT DEVELOPMENTS
29.12 TAKEDA PHARMACEUTICALS
29.12.1 COMPANY OVERVIEW
29.12.2 REVENUE ANALYSIS
29.12.3 GEOGRAPHIC PRESENCE
29.12.4 PRODUCT PORTFOLIO
29.12.5 RECENT DEVELOPMENTS
29.13 JANSSEN PHARMACEUTICALS (JOHNSON & JOHNSON)
29.13.1 COMPANY OVERVIEW
29.13.2 REVENUE ANALYSIS
29.13.3 GEOGRAPHIC PRESENCE
29.13.4 PRODUCT PORTFOLIO
29.13.5 RECENT DEVELOPMENTS
29.14 MYLAN N.V
29.14.1 COMPANY OVERVIEW
29.14.2 REVENUE ANALYSIS
29.14.3 GEOGRAPHIC PRESENCE
29.14.4 PRODUCT PORTFOLIO
29.14.5 RECENT DEVELOPMENTS
29.15 CANARIABIO INC
29.15.1 COMPANY OVERVIEW
29.15.2 REVENUE ANALYSIS
29.15.3 GEOGRAPHIC PRESENCE
29.15.4 PRODUCT PORTFOLIO
29.15.5 RECENT DEVELOPMENTS
29.16 HIKMA PHARMACEUTICALS
29.16.1 COMPANY OVERVIEW
29.16.2 REVENUE ANALYSIS
29.16.3 GEOGRAPHIC PRESENCE
29.16.4 PRODUCT PORTFOLIO
29.16.5 RECENT DEVELOPMENTS
29.17 FRESENIUS KABI AG GERMANY
29.17.1 COMPANY OVERVIEW
29.17.2 REVENUE ANALYSIS
29.17.3 GEOGRAPHIC PRESENCE
29.17.4 PRODUCT PORTFOLIO
29.17.5 RECENT DEVELOPMENTS
29.18 ABBVIE
29.18.1 COMPANY OVERVIEW
29.18.2 REVENUE ANALYSIS
29.18.3 GEOGRAPHIC PRESENCE
29.18.4 PRODUCT PORTFOLIO
29.18.5 RECENT DEVELOPMENTS
29.19 PHARMAMAR
29.19.1 COMPANY OVERVIEW
29.19.2 REVENUE ANALYSIS
29.19.3 GEOGRAPHIC PRESENCE
29.19.4 PRODUCT PORTFOLIO
29.19.5 RECENT DEVELOPMENTS
29.2 GSK PLC
29.20.1 COMPANY OVERVIEW
29.20.2 REVENUE ANALYSIS
29.20.3 GEOGRAPHIC PRESENCE
29.20.4 PRODUCT PORTFOLIO
29.20.5 RECENT DEVELOPMENTS
29.21 AKESO BIOPHARMA CO., LTD
29.21.1 COMPANY OVERVIEW
29.21.2 REVENUE ANALYSIS
29.21.3 GEOGRAPHIC PRESENCE
29.21.4 PRODUCT PORTFOLIO
29.21.5 RECENT DEVELOPMENTS
29.22 CHIPSCREEN BIOSCIENCES
29.22.1 COMPANY OVERVIEW
29.22.2 REVENUE ANALYSIS
29.22.3 GEOGRAPHIC PRESENCE
29.22.4 PRODUCT PORTFOLIO
29.22.5 RECENT DEVELOPMENTS
29.23 SHANGHAI HENLIUS BIOTECH
29.23.1 COMPANY OVERVIEW
29.23.2 REVENUE ANALYSIS
29.23.3 GEOGRAPHIC PRESENCE
29.23.4 PRODUCT PORTFOLIO
29.23.5 RECENT DEVELOPMENTS
29.24 BAYER
29.24.1 COMPANY OVERVIEW
29.24.2 REVENUE ANALYSIS
29.24.3 GEOGRAPHIC PRESENCE
29.24.4 PRODUCT PORTFOLIO
29.24.5 RECENT DEVELOPMENTS
29.25 IPSEN PHARMA
29.25.1 COMPANY OVERVIEW
29.25.2 REVENUE ANALYSIS
29.25.3 GEOGRAPHIC PRESENCE
29.25.4 PRODUCT PORTFOLIO
29.25.5 RECENT DEVELOPMENTS
29.26 EISAI
29.26.1 COMPANY OVERVIEW
29.26.2 REVENUE ANALYSIS
29.26.3 GEOGRAPHIC PRESENCE
29.26.4 PRODUCT PORTFOLIO
29.26.5 RECENT DEVELOPMENTS
29.27 JAZZ PHARMACEUTICALS, INC
29.27.1 COMPANY OVERVIEW
29.27.2 REVENUE ANALYSIS
29.27.3 GEOGRAPHIC PRESENCE
29.27.4 PRODUCT PORTFOLIO
29.27.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
30 RELATED REPORTS
31 CONCLUSION
32 QUESTIONNAIRE
33 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
